At a Glance
- Company: Blue Arbor Technologies
- Location: Undisclosed (US-based neurotech focus)
- Deal value: $5 million USD investment
- Focus area: RESTORE neuromuscular interface system
- Next steps: Clinical validation, commercial prototyping
What happened?
Blue Arbor Technologies announced on 26 February 2026 a $5 million investment from Ottobock, paired with a strategic partnership to accelerate development of the RESTORE neuromuscular interface system. RESTORE enables intuitive prosthetic control by decoding neural signals from residual limb muscles, translating intent into natural movement.
Why does it matter?
Current prosthetics rely on limited EMG surface electrodes, yielding ~60% functionality vs able-bodied motion; RESTORE’s implanted interface promises 90%+ intuitive control, reducing cognitive burden and improving quality of life for 2M+ US amputees. Partnership validates technology amid $10B global prosthetics market growth.
Who’s behind it?
Blue Arbor develops bioelectronic implants; Ottobock, a 110-year-old prosthetics leader, brings manufacturing/regulatory expertise. CEOs emphasised complementary strengths in neural decoding and commercial scaling.
How was it achieved?
RESTORE uses fine-wire electrodes implanted in residual muscles to capture high-fidelity motor signals, processed via onboard AI for real-time prosthetic actuation. Early human data shows precise finger-level control; funding supports pivotal trials and miniaturisation.
What’s next?
Clinical studies expand 2026; Ottobock aids FDA pathway targeting 2028 market entry. Funds build manufacturing and integration with Ottobock’s Michelangelo/Esprit lines.
What are people saying?
Blue Arbor CEO: “RESTORE redefines prosthetic control.” Ottobock exec: “Breakthrough partnership for intuitive mobility.”